In The News

SystImmune, Inc. to Present Updated BL-B01D1 Data in Breast Cancer at SABCS Congress 2024

Redmond, Washington     December 11th, 2024

SystImmune, Inc. Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting

Redmond, Washington     November 26th, 2024

SystImmune, Inc. Announces FDA Clearance of IND Application for BL-M17D1 in Advanced Solid Tumors

Redmond, Washington     November 8th, 2024

SystImmune, Inc. Announces FDA Clearance of IND Application for BL-M11D1 in Relapsed/Refractory Acute Myeloid Leukemia

Redmond, Washington     October 14th, 2024

SystImmune, Inc. to Present New BL-B01D1 Data in Urothelial, Biliary Tract, and Esophageal Squamous Cell Carcinoma at ESMO Congress 2024

Redmond, Washington     September 9th, 2024

SystImmune, Inc. Announces the Appointment of Dr. Jonathan Cheng as New Chief Medical Officer D’Elia as Chief Executive Officer

Redmond, Washington     May 23rd, 2024

SystImmune,Inc. Appoints Dr. Jie D’Elia as Chief Executive Officer

Redmond, Washington     April 22nd, 2024

SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1

Redmond, Washington     December 11th, 2023

SystImmune, Inc. Announces the Presentation of Breast Cancer Clinical Trial Results at the 2023 San Antonio Breast Cancer Conference and US Clinical Trial Developments.

Redmond, Washington     December 5th, 2023

SystImmune, Inc. to Present New Oncology Pipeline Data at ESMO Congress 2023

Redmond, Washington     October 20th, 2023

SystImmune, Inc. Announces First Patient Dosed in U.S. Phase 1 Clinical Trial of BL-B01D1 for the Treatment of Metastatic or Unresectable Non-Small Cell Lung Cancer

Redmond, Washington     October 10th, 2023

SystImmune, Inc. Announces FDA Clearance of IND Application for BL-B01D1, a Bi-specific Antibody Drug Conjugate Targeting EGFR and HER3, Enabling Initiation of Phase 1 Clinical Trials for the Treatment of Metastatic or Unresectable Non-Small Cell Lung Cancer

Redmond, Washington     July 1st, 2023

BL-B01D1 Phase 1 clinical data from ASCO 2023: commentary by oncologists featured on OncLive

Redmond, Washington     June 8th, 2023

SystImmune, Inc. to Present New Data from Oncology Programs at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2023

Redmond, Washington     May 1st, 2023

Leaders in Breast and Lung Cancer treatment join SystImmune, Inc.’s Clinical Science Advisory Committee

Redmond, Washington     April 26th, 2023

SystImmune, Inc. to Present Data from Seven Preclinical Programs at the American Association of Cancer Research (AACR) Annual Meeting 2023

Redmond, Washington     April 14th, 2023

Biokin Pharmaceutical Launches Shanghai Initial Public Offering

Chengdu, China     Jan, 2023

Baili Announces Clinical Trial Collaboration to Evaluate SI-B001, an EGFR x HER3 bispecific Antibody, in Combination with Tagrisso® in Patients with Non-Small Cell Lung Cancer

Redmond, Washington     May 13rd, 2022

SystImmune, Inc. Announces Appointment of Martín Sebastian Olivo, M.D. as Chief Medical Officer

Redmond, Washington     February 7th, 2022

Systimmune, Inc. Announces SI-F019 As a Blocker of Viral Entry against SARSCoV-2 with Reduced Inflammatory Risk

Redmond, Washington     March, 2020

High Throughput Application of High Resolution LC-MS for Upstream and Downstream Biotherapeutics Process Development

Pleasanton, California     August, 2018

ACS National Meeting 2018 - Rapid aggregate reduction of bi-specific antibody model by filtration

New Orleans, Louisiana     March, 2018